November 09, 2022

| To | To |
| :--- | :--- |
| The Manager, Listing Department | The General Manager, Listing Department |
| National Stock Exchange of India Limited | BSE Limited |
| Plot no. C/1 G Block, | Phiroze Jeejeebhoy Towers, |
| Bandra-Kurla Complex, Bandra (East), | Dalal Street, |
| Mumbai- 400051 | Mumbai- $\mathbf{4 0 0} 001$ |
| Symbol: BLISSGVS | Scrip Code: 506197 |

Dear Sir/Madam,
Subject: Newspaper Advertisement of Unaudited Financial Results for the quarter and half year ended September 30, 2022

Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022 published in 'The Economic Times \& The Free Press Journal' an English Daily and 'Maharashtra Times \& Navshakti' a Regional Daily, on November 09, 2022.

Kindly take the same on record.

Thanking you.

Yours faithfully, For Bliss GVS Pharma Limited


Encl: as above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771
Factory : Plot No. 10, 11 \& 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. \& Dist. Palghar - 401404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. •Email : factory@blissgvs.com


## SC slams prosecution in gangrape-murder case

While acquitting three accused men, court says prosecution failed to provide leading, cogent, clinching and clear evidence
$\qquad$
'Centre using governors to encroach on states' powers where horse-trading not possible'



On his last working day, Lalit bows down before court

NATION 13


last 37 years at the SC
29 yearas as a a lawyer
last eight 29 years as a lawyer and th
last eight as a judge - took
final tour of the court final tour of the court on
Tuesday evening, Bar and
Bench reported Bench reported. A person
who retires as a judge of the who retires as a judge of the
SC is not allowed to practice
as a lawyer in any court after as a lawyer in any
s/he demits office.
$\qquad$

|  |
| :---: |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

## 3liss

| Edelweiss Rural \& Corporate Services Limited |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  <br> Financial Results for the quarter ended September 30, 2022 |  |  |  |  |
|  | Particulars | $\begin{aligned} & \text { Quarte } \\ & \text { September } \\ & \text { 30, } 2022 \\ & \text { (Unaudited) } \end{aligned}$ |  | Year Ended March 31, 2022 (Audited) |
|  | Revenue fom operations | ${ }^{23,69}$ | 26901 | 1.084 |
|  |  | 15.05 | 0.6) | ${ }^{(8205)}$ |
|  |  | 15.05 | (40.66) | ${ }^{882051}$ |
|  |  | 3.2 | (41.18) | ${ }^{17.60)}$ |
|  | Total Comprenensive lin | ${ }_{3} 38$ | ${ }^{40.90)}$ | ${ }^{(76.41)}$ |
|  | Patay edity | 46.54 | 39.78 | 46.54 |
|  | eses exciuding Revaluation Reseses) | 5119 | 80.72 | 491.18 |
|  | Securifes Pre | 507.81 | 26445 | 50781 |
|  | Networt | 64.77 | 414.19 | 62.26 |
|  | Paidup Deetc Capiala/ Oustanding oeebt | 2.551 .03 | 4,497.12 | 3,508.71 |
|  | Outsanding Redeemale Pereferene | 233.11 | 24.58 | 223.45 |
|  | Debt Equitreatio | 3.94 | 10.86 | ${ }_{5.58}$ |
|  |  |  |  |  |
|  | Basic (Notamualised) | 0.45 | (6.28) | (11.38) |
|  | - ilited (Notanuaised) | 0.45 | ${ }^{16.23}$ |  |
|  | Capita Redempion Resere | 3.00 | 3.00 | 3.00 |
|  | Defenture edeemprion Reseeve | ${ }^{120.21}$ | 235.62 |  |
|  |  | 0.12 | 0.03 |  |
|  | Interest Service Coverage Ratio (ISCR) <br> (Not annualised) | ${ }^{1.16}$ | 0.66 |  |
|  |  |  |  |  |
| Notes |  |  |  |  |
|  <br>  |  |  |  |  |
| - |  |  |  |  |
| the URL( website:- https://ercsl.edelweissfin.com/).3 The above financial results of Edelweiss Rural \& Corporate Services Limited ('the Company') for the quarter andhalf year ended September 30, 2022 have been reviewed and recommended by the Audit Committee and |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  | On behalf of the Board of Directors <br> Ravindra Dhobale |  |  |
|  | ai. Noememer, 2022 | Ravindra DhobaleExecutive Director and Chief Financial OfficerDIN.: 05147051 |  |  |

EXTRAGT OF STATEMENT OF UNAUDITED STANDALONE AND GONSOLIDATED FINANGIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

| Particulars | STANDALONE |  |  |  |  |  | Consolidated |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Quarter ended |  |  | half year enoed |  |  | Quarter ended |  |  | half year enoed |  |  |
|  | 99.2022 | 0.06.20 | 30. | 30.09.2 | 30.09.2021 |  | 30.09.2022 | 30.06.2 | 30.09.2021 | 30.09.2022 | 30.09.2 |  |
|  | un-au\|ited | UN-Auotite | Un-Audite | UN-Auoted | UN-40\|ted | Audited | un-auored | U-.40пted | UN-AuDIted | UN-Aטotite | U-.-טणाזED | audit |
| Total Income from Operations (net) | 15,307.98 | 16,591.34 | 18,041.49 | 31,899.32 | 32,134.08 | 66,888.46 | 17,458.10 | 19,567.25 | 20,143.74 | 37,025.35 | 37,740.00 | 77,894.60 |
| Profit before Tax \& Excepionali item | 3,529.20 | 3,20.59 | 3,47.01 | 6,73.79 | 6,381.44 | 12,365.52 | 2,091.06 | 3,991.85 | 2,988.64 | 5,938.9 | 6,657.23 | 12,775.98 |
| Profit before Tax | 3,529.20 | 3,206.59 | 3,47.01 | 6,73.79 | 6,38.44 | 12,640.03 | 2,019.06 | 3,919.85 | 2,988.64 | 5,938.9 | 6,657.2 | 5,416 |
| Net Profit or the period | 2,544.68 | 2,464.52 | 2,472.74 | 5,09.20 | 4,63.54 | 9,266.40 | 1,600 | 2,747.9 | 2,205.9 | 4,348. | 4,819.0 | 2,312 |
| Total Comprehensive Income for the period | 2,475.01 | 2,488.93 | 2,462.57 | 4,963.94 | 4,639.55 | 9,296.67 | 1,429.23 | 2,573.46 | 2,218.55 | 4,002.69 | 4,760.38 | 1,571 |
| Equity Share Capital | 1,038.85 | 1,038.08 | 1,035.09 | 1,038.85 | 1,035.09 | 1,036.78 | 1,038.85 | 1,038.08 | 1,035.09 | 1,038.85 | 1,035.09 | 1,036.78 |
| Other Equity | 88,950.43 | 86,234.95 | 79,221.67 | 88,950.43 | 79,221.67 | 84,106.29 | 84,311.06 | 82,856.63 | 84,336.33 | 84,311.06 | 84,336.33 | 80,833.39 |
| Earnings Per Share (Not annualised) |  |  |  |  |  |  |  |  |  |  |  |  |
| 1. Basic (z) | 2.45 | 2.38 | 2.39 | 4.82 | 4.48 | 8.97 | 1.33 | 2.48 | 2.05 | 3.8 | 4.40 | . 6 |
| ii. Diluted (\%) | 2.41 | 2.34 | 2.34 | 4.75 | 4.38 | 8.81 | 1.31 | 2.44 | 2.01 | 3.75 | 54.30 | 1.43 |
| Note: <br> (1) The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Half year ended September 30, 2022 and Annual Result for the Yearended March 31,2022 are filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br> The figures for the quarter ended $S$ September 30,2022 are the balancing figures between unaudited figures in respect of the half year ended September 30,2022 and the year to date published figures for the quarter ended June $30,2022$. <br> (2) The full format of the Standalone and Consolidated financial results for the Quarter and Half year ended September 30,2022 and Annual Result for the Year ended March 31,2022 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.bissgys.com. <br> (3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rulus issued there under. <br> (4) During the year ended March 31,2022 , with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Biss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD $3,75,000$ vide agreement dated 25 th Nov, 2021 and is derecognised in the year ended March 31,2022 , though the consideration is received on January 5,2022 and the concerned shares were transferred on January $12,2022$. (5) During the year ended March 31,2022 , standalone financials statements includes exceptional item ₹ 274.51 Lakh, being profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore. <br> For BLISS GVS PHARMA LIMITED SD/- <br> Place : Mumbai <br> GAGAN HARSH SHARMA <br> MANAGING DIRECTOR Din No : 07939421 |  |  |  |  |  |  |  |  |  |  |  |  |




